Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

The Rockefeller University

Tomohiro Okawa

Yasufumi Miyamoto

Akito Shibuya

Hideyuki Sugiyama

Masataka Murakami

Hideo Suzuki

Junya Shirai

Keiko Kakegawa

Hironobu Maezaki

Yasutomi Asano

Ayumu Sato

Jinichi Yonemori

Yasuhiro Hirata

Jumpei Aida

Seiji Miwatashi

Zenyu Shiokawa

Yuta Tanaka

Nobuyuki Matsunaga

Yuko Hitomi

Takashi Nakahata

Minoru Nakamura

Hidekazu Tokuhara

Kazuaki Takami

Masaki Ogino

Hideki Furukawa

Shuhei Ikeda

Shinobu Sasaki

Koji Watanabe

Masahiro Ito

Takeshi Yamasaki

Masaki Seto

Malcolm Maccoss

Takuto Kojima

Masami Yamada

Xiaolun Wang

Toshihiro Imaeda

Haruhi Ando

Yuya Oguro

Nobuyuki Takakura

Yasuyoshi Arikawa

Nicholas Scorah

Minoru Sasaki

Minoru Yoshida

John S Tyhonas

Tohru Miyazaki

Mark Sabat

Phong H Vu

Terufumi Takagi

Ikuo Fujimori

Yasuhiro Imaeda

Joanne Miura

Makoto Fushimi

Fumiaki Kikuchi

Kenichiro Shimokawa

Rei Okamoto

Yoichi Nishikawa

Takeshi Wakabayashi

Haixia Wang

Yoshito Terao

Takafumi Yukawa

Misaki Homma

Lily Kwok

Mallareddy Komandla

Akinori Toita

Tomohiro Ohashi

Takeshi Yoshikawa

Hironori Kokubo

Steve Swann

Naoyoshi Noguchi

Tomoko Ohashi

Hiroki Takahagi

Osamu Kubo

Yasuhiro Tsukimi

Paul Tanis

Yayoi Yoshitomi

Takeshi Yamamoto

Masato Yoshikawa

Tatsuki Koike

Makoto Kamata

Norihito Tokunaga

Yuhei Miyanohana

Tsuyoshi Maekawa

Shizuo Kasai

Toshitake Kobayashi

Zenichi Ikeda

Eiji Kimura

Michael Andrew Foley

Moriteru Asano

Kazuyoshi Aso

Yayoi Nakayama

Tarun M Kapoor

Yoshiyuki Fukase

Takeshi Yasui

Yuki Hanya

Akira Kawada

Shiinobu Sasaki

Hirotaka Kamitani

Yashuhiro Hirata

Sachie Takashima

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description,or a pharmaceutically acceptable salt thereof.

Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors

The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

Compounds of formula: are useful as antitumor agents. In these compounds, Ris (a) (C-C) hydrocarbyl, (C-C)halohydrocarbyl, (C-C)hydroxyalkyl, or or Ris (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.

Pyrazoloquinazolinone antitumor agents

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Aminopyrimidine compound

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): 

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

HDAC6 inhibitory heterocyclic compound

Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Aromatic compounds with GPR40 agonistic activity

Growing community of inventors

Kanagawa, Japan

Tomohiro Okawa